Carcinoma of Unknown Primary Site (CUP) a comparison across tissue and liquid biomarkers (CUP-COMP)

原发部位不明的癌 (CUP) 组织和液体生物标志物的比较 (CUP-COMP)

• 批准号: 50074
• 金额: $ 87.78万
• 依托单位: ROCHE PRODUCTS LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=50074
• 关键词: Carcinoma; Unknown; Primary; Site; CUP

Patients with Carcinoma of Unknown Primary (CUP) have widespread cancer at diagnosis however the specific site of origin cannot be found making it difficult to treat. CUP is a common cancer with a poor prognosis. It is the 6th most common cause of cancer death in the UK. Every day approximately 20 people are diagnosed and 30 people die from CUP (CRUK Statistics).CUP demands that we integrate everything we know about the patient's cancer: patient's symptoms, blood test results, radiological imaging and pathology results are all currently used as standard diagnostics to make clinical decisions for CUP patients. To date there have been limited studies investigating molecular genomics in CUP patients, as a result we have limited evidence to evaluate whether genomic profiling has added value over and above the standard diagnostics provided in the NHS.As a result, our project will focus on addressing the following;* Assessment of genomic sequencing (both in tissue and blood) for the diagnosis and treatment stratification in patients with CUP including a comparison of the effectiveness of tissue and blood based biomarkers* Collection of evidence to further develop technology that predicts an individual's response to a treatment* Development of innovative systems of clinical data capture in patients with CUP* Investigation into novel biomarkers to determine the primary tumour locationThis collaboration unites experts from 7 academic institutions linked to NHS Hospitals and Cancer Research UK, a pharmaceutical company with access to a number of novel therapeutics (Roche), expert data management (ConcR) alongside patient representatives from the CUP Foundation Jo's Friends.The UK CUP Investigators are dedicated to improving prognosis and access to treatments in CUP. In order to make further progress for our patients we need to be able to consent and molecularly profile increased numbers of patients. This project will aim to enroll patients across all subtypes of CUP, gathering evidence for the multitude of questions that remain unanswered. The genomic and longitudinal clinical data that will be collected would be the first dataset to include multi-omic and clinical data and could be used to drive additional research in the UK. It would address an area of high unmet need and has the potential to change clinical care.

原发不明癌(CUP)患者确诊时肿瘤分布广泛，但具体来源不明，治疗困难。杯状细胞癌是一种常见的癌症，预后差。在英国，它是第六大常见癌症致死原因。每天约有20人被诊断，30人死于CUP(CRUK统计)。CUP要求我们整合我们所知道的关于患者癌症的一切：患者的症状、血液测试结果、放射成像和病理结果目前都被用作为CUP患者做出临床决策的标准诊断。到目前为止，研究CUP患者的分子基因组学的研究有限，因此我们没有有限的证据来评估基因组图谱是否具有超出NHS提供的标准诊断的附加值。因此，我们的项目将专注于解决以下问题；*评估基因组测序(在组织和血液中)对CUP患者的诊断和治疗分层，包括组织和血液生物标志物有效性的比较*收集证据以进一步开发预测个人对治疗的反应的技术*开发CUP患者临床数据捕获的创新系统*调查新的生物标志物以确定主要肿瘤位置这项合作联合了7个学术机构的专家，这些机构与NHS医院和英国癌症研究机构有联系，该公司是一家可以获得许多新疗法(罗氏)的制药公司，专家数据管理(CONR)与来自CUP基金会乔的朋友的患者代表一起。英国CUP调查人员致力于改善CUP的预后和获得治疗的机会。为了我们的患者取得进一步的进展，我们需要能够同意并对更多的患者进行分子图谱分析。该项目的目标是招募所有亚型的患者，为仍未回答的众多问题收集证据。将收集的基因组和纵向临床数据将是第一个包括多组和临床数据的数据集，并可用于推动英国的其他研究。它将解决一个高度未得到满足的需求领域，并有可能改变临床护理。